| pubmed-article:17187291 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0030567 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0037663 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0003596 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0114838 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0039593 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0022885 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:17187291 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:17187291 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17187291 | pubmed:dateCreated | 2007-4-25 | lld:pubmed |
| pubmed-article:17187291 | pubmed:abstractText | Challenge with low-dose apomorphine causes a rise in growth hormone (GH) in patients with Parkinson's disease (PD). We studied 18 patients with early PD, who showed an increase of GH in the low-dose apomorphine test, by means of [(123)I] FP-CIT-SPECT. The mean specific dopamine transporter binding of the 18 patients was 1.50 +/- 0.56 in the striatum, 1.20 +/- 0.59 in the putamen, and 1.76 +/- 0.59 in the caudate nucleus. The increase of GH (1.05 +/- 1.01 ng/ml at baseline to 9.46 +/- 6.36 ng/ml 45 min after apomorphine injection; p < 0.001) was significant. There was a significant negative correlation of the increase of GH with the mean specific dopamine transporter binding in all three regions (r between -0.490 and -0.587; p between 0.04 and 0.01). Challenge with low-dose apomorphine may therefore be used as an indirect tool to measure the extent of nigrostriatal neurodegeneration in early PD. | lld:pubmed |
| pubmed-article:17187291 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17187291 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17187291 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17187291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17187291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17187291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17187291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17187291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17187291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17187291 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17187291 | pubmed:issn | 0300-9564 | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:WuttkeWW | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:MellerJJ | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:KochWW | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:PaulusWW | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:WelschJJ | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:TatschKK | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:TrenkwalderCC | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:HappeSS | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:TingsTT | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:BaierP CPC | lld:pubmed |
| pubmed-article:17187291 | pubmed:author | pubmed-author:HelmschmiedKK | lld:pubmed |
| pubmed-article:17187291 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17187291 | pubmed:volume | 114 | lld:pubmed |
| pubmed-article:17187291 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17187291 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17187291 | pubmed:pagination | 589-94 | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:meshHeading | pubmed-meshheading:17187291... | lld:pubmed |
| pubmed-article:17187291 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17187291 | pubmed:articleTitle | Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease. | lld:pubmed |
| pubmed-article:17187291 | pubmed:affiliation | Department of Clinical Neurophysiology, University of Göttingen, Göttingen, Germany. Svenja.Happe@klinikum-bremen-ost.de | lld:pubmed |
| pubmed-article:17187291 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17187291 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:6531 | entrezgene:pubmed | pubmed-article:17187291 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17187291 | lld:entrezgene |
